Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice

Behavioural Pharmacology

Volumn 18, Issue 7, 2007, Pages 691-697

  Jafari, Mohammad R ^a   Golmohammadi, Somaye ^b   Ghiasvand, Fereshteh ^b   Zarrindast, Mohammad R ^c   Djahanguiri, Bijan ^c  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antinociception; Formalin test; JWH133; Mouse; Nicotinic receptors

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; FORMALDEHYDE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR;

ANALGESIC ACTIVITY; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN;

ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMALDEHYDE; MALE; MECAMYLAMINE; MICE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PAIN; PAIN THRESHOLD; RECEPTOR, CANNABINOID, CB2; RECEPTORS, NICOTINIC;

EID: 34948820163     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282f00c10     Document Type: Article

References (40)

1. Anikwue R, Hufman JW, Martin ZL, Welch SP (2002). Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic Δ9-tetrahydrocannabinol administration. J Pharmacol Exp Ther 303:340-346.
2. Armstrong RA, Hilton A (2004). The use of analysis of variance (ANOVA) in applied microbiology. Microbiologist 5:418-421.
3. Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R (2004). Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20:2737-2748.
4. Brooks JW (2002). Cannabinoids and analgesia. Curr Anaesth Crit Care 13:215-220.
5. Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, Brizzi A, et al. (2006). In vitro and in vivo pharmacology of synthetic olivetol- or resorcinolderived cannabinoid receptor ligands. Br J Pharmacol 149:431-440.
6. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394:277-281.
7. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT (2002). CB1 and CB2 annabinoid receptors are implicated in inflammatory pain. Pain 96:253-260.
8. Dubuisson D, Dennis SG (1977). The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161-174.
9. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92:3376-3380.
10. Flood P, Sonner JM, Gong D, Coates KM (2002). Isoflurane hyperalgesia is modulated by nicotinic inhibition. Anesthesiology 97:192-198.
11. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
12. Green A, O'Shaughnessy C, Disney G, Marshall F (1999). Receptor assays for human cannabinoid CB1 and CB2 receptors for the identification of novel agonists. Br J Pharmacol 126:112P.
13. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, et al. (1999). Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: further evidence of cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377:117-125.
14. Hanu L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (1999). HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96:14228-14233.
15. Hohman AG, Herkenham M (1999a). Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92:1171-1175.
16. Hohman AG, Herkenham M (1999b). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90:923-931.
17. Ho BY, Uezono Y, Takada S, Takase I, Izumi F (1999). Coupling of cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K1 channels. Receptors Channels 6:363-374.
18. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, et al. (1999). 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905-2914.
19. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100:10529-10533.
20. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093-3098.
21. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. (2006). CB2 cannabinoid receptor mediation of antinociception. Pain 122:36-42.
22. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC (1998). The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189-199.
23. Jones BC, Consroe PF, Laird HE II (1976). The interaction of delta9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm. Eur J Pharmacol 38:253-259.
24. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245.
25. Molinero MT, Del Rio J (1987). Substance P, nicotinic acetylcholine receptors and antinociception in the rat. Neuropharmacology 26:1715-1720.
26. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
27. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG (2004). Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92:3562-3574.
28. Onaivi ES (2006). Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54:231-246.
29. Parvini S, Hamann SR, Martin WR (1993). Pharmacologic characteristics of a medullary hyperalgesic center. J Pharmacol Exp Ther 265:286-293.
30. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
31. Pryor GT, Larsen FF, Husain S, Braude MC (1978). Interactions of delta9-tetrahydrocannabinol with D-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 8:295-318.
32. Richardson JD, Kilo S, Hargreaves KM (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119.
33. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurons: implications for antinociception. Neuropharmacology 40:221-232.
34. Sahley TL, Berntson GG (1979). Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacol 65:279-283.
35. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992). The formalin test: an evaluation of the method. Pain 51:5-17.
36. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658-672.
37. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R (2002). Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135:564-578.
38. Viveros MP, Marco EM, File SE (2006). Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci Biobehav Rev 30:1161-1181.
39. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83:1310-1322.
40. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5338-5339.